Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.
Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C. Vigneron N, et al. Among authors: krieger s. Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2. Mol Oncol. 2016. PMID: 27083764 Free PMC article.
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Lheureux S, et al. Among authors: krieger s. Int J Gynecol Cancer. 2012 Nov;22(9):1483-8. doi: 10.1097/IGC.0b013e31826d1438. Int J Gynecol Cancer. 2012. PMID: 23027040 Clinical Trial.
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
Jamard E, Volard B, Dugué AE, Legros A, Leconte A, Clarisse B, Davy G, Polycarpe F, Dugast C, Abadie C, Frebourg T, Tinat J, Tennevet I, Layet V, Joly F, Castéra L, Berthet P, Vaur D, Krieger S. Jamard E, et al. Among authors: krieger s. Fam Cancer. 2017 Apr;16(2):167-171. doi: 10.1007/s10689-016-9940-2. Fam Cancer. 2017. PMID: 27783335 Clinical Trial.
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F. Jacquemier J, et al. Among authors: krieger s. BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351. BMC Cancer. 2013. PMID: 23875536 Free PMC article.
OutLyzer: software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice.
Muller E, Goardon N, Brault B, Rousselin A, Paimparay G, Legros A, Fouillet R, Bruet O, Tranchant A, Domin F, San C, Quesnelle C, Frebourg T, Ricou A, Krieger S, Vaur D, Castera L. Muller E, et al. Among authors: krieger s. Oncotarget. 2016 Nov 29;7(48):79485-79493. doi: 10.18632/oncotarget.13103. Oncotarget. 2016. PMID: 27825131 Free PMC article.
318 results